Search

Displaying results 1971 - 1980 of 5419 in total
  1. Drug

    Bromodiphenhydramine

    go.drugbank.com/drugs/DB01237
    Approved

    Bromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.

    Categories: Antihistamines for Systemic Use
  2. Drug

    Cefotetan

    go.drugbank.com/drugs/DB01330
    ApprovedInvestigational

    A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positi...

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [A256828,A256863,L44948] Other types of endocrine therapy, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), may lead to drug resistance over time; therefore, the use … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

  4. Drug

    rhMBL

    go.drugbank.com/drugs/DB05237
    Investigational

    MBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).

  5. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not

  6. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it

  7. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  8. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).

  9. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective ag...

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Procaine benzylpenicillin

    go.drugbank.com/drugs/DB09320
    ApprovedVet approved

    Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use